Everything You Need to Know About Retatrutide

Retatrutide — sometimes called Reta or GLP-3, is the latest weight loss peptide. This post is a primer for someone who's heard the name and wants to understand what it actually is, how it differs from the GLP-1 medications already available, what the latest clinical trial data shows.

First: What the GLP-1 Class Is and Why Retatrutide Is Different

To understand retatrutide, you need a brief picture of the class it belongs to and what came before it.

GLP-1 is a hormone your gut releases after eating. It signals to the brain that you're full, slows gastric emptying, and stimulates insulin release. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist which means it mimics and amplifies the natural GLP-1 signal, producing appetite suppression and weight loss. Phase 3 trials showed approximately 15% average body weight reduction at 68 weeks.

Tirzepatide (Mounjaro, Zepbound) added a second receptor target: GIP, which is another gut hormone involved in insulin secretion, appetite, and fat storage. As a dual-acting drug, tirzepatide outperformed semaglutid. Phase 3 trials showed approximately 20–22% average body weight reduction. Another step forward.

Retatrutide is a triple agonist: a single molecule that activates the body's receptors for GIP, GLP-1, and glucagon. It's developed by Eli Lilly, the same company behind tirzepatide, and it adds the glucagon receptor as a third target.

That third receptor is the key differentiator, and understanding what it does explains why retatrutide is producing results beyond what dual agonists achieved.

It Helps If You Understand What Each Receptor Does

GLP-1 receptor: Reduces your appetite, slows gastric emptying so you feel full longer, and stimulates glucose-dependent insulin release. This is the core mechanism behind all compounds in this class.

GIP receptor: Enhances insulin secretion, may improve GLP-1 receptor sensitivity (explaining why the dual agonist outperforms the mono-agonist), and appears to have some direct effects on fat storage and bone density. GIP receptor activity may also be partially protective against the bone density loss that accompanies rapid weight reduction.

Glucagon receptor: This is the addition that changes the equation. Glucagon is classically known as a counter-regulatory hormone. It raises blood glucose when you haven't eaten. But glucagon receptor activation also does something else: it increases fat burning and raises energy expenditure. The addition of glucagon receptor activity is what makes retatrutide different from everything that came before it. Semaglutide and tirzepatide primarily work by reducing how much you eat, while retatrutide does that and increases how much energy your body uses, shifting metabolism to burn stored fat more aggressively.

This dual action, less in, more burned, is why the weight loss numbers are larger than with earlier generation compounds.

The liver fat data is perhaps the most dramatic illustration of the glucagon component at work. In a Phase 2a trial published in Nature Medicine, retatrutide produced up to 82% reduction in liver fat at 24 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

What the Clinical Trials Show

Retatrutide is in an active Phase 3 program called TRIUMPH, spanning multiple indications. The evidence has accumulated rapidly over the past 18 months.

Phase 2 (NEJM, 2023): The landmark paper that put retatrutide on the map. In 338 adults with obesity, retatrutide at the highest dose (12 mg) produced average body weight reduction of 24.2% at 48 weeks. That's the highest weight loss figure ever reported in a pharmaceutical trial at that timepoint, surpassing both semaglutide and tirzepatide. In the type 2 diabetes substudy, 77–82% of participants on retatrutide achieved euglycaemia (HbA1c ≤ 6.5%) at 36 weeks, and 57–63% achieved ≥ 15% weight loss.

TRIUMPH-4 (Phase 3, December 2025): Eli Lilly announced positive topline results from TRIUMPH-4, evaluating retatrutide in adults with obesity and knee osteoarthritis. At 68 weeks, the 12 mg dose produced an average of 71.2 lbs of weight loss — approximately 28.7% body weight reduction — alongside significant improvement in WOMAC pain scores, with more than one in eight participants becoming completely free of knee pain.

TRIUMPH-1 (Phase 3, May 2026): The most important trial for FDA purposes. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. Full numerical results are pending publication but topline results confirm the Phase 2 weight loss magnitude held through a longer, larger trial.

TRANSCEND-T2D-1 (Phase 3, March 2026): In adults with type 2 diabetes, retatrutide met the primary and all key secondary endpoints at 40 weeks, delivering superior HbA1c reduction and weight loss compared to placebo.

Lilly is studying retatrutide across several additional Phase 3 trials including cardiovascular outcomes, sleep apnea, chronic low back pain, and MASLD — indications that reflect how far the metabolic medicine field has moved from thinking of these as simply "weight loss drugs."

What It Might Be Approved For

Based on the completed Phase 3 trials and those still reporting through 2026, the most likely initial indication is obesity and overweight with at least one weight-related comorbidity — the same broad indication as Wegovy and Zepbound. Type 2 diabetes is a near-certain additional indication given the TRANSCEND-T2D-1 results.

The osteoarthritis pain results from TRIUMPH-4 are notable and potentially indicate a meaningful secondary indication — the weight loss itself drives much of the joint pain improvement (reduced mechanical load), but the magnitude of pain relief was striking enough to support the indication separately.

Eli Lilly has not yet submitted an NDA (New Drug Application) to the FDA. Given that Phase 3 trials are completing through 2026, the manufacturer will likely apply soon. After submission, the FDA typically reviews within 6–10 months. Given this timeframe, FDA approval could come in 2027.

The Pros: Why This Peptide Is Generating Excitement

Weight loss magnitude that exceeds anything currently approved. Phase 2 showed 24% at 48 weeks. Phase 3 TRIUMPH-4 showed 28.7% at 68 weeks. For context: most people with obesity need to lose 10–15% of body weight to meaningfully reduce metabolic disease risk, and most prior pharmacotherapy achieved 5–10%. Retatrutide is reaching weight loss magnitudes previously associated only with bariatric surgery.

Liver fat reduction in a class of its own. The 82% liver fat reduction at 24 weeks in the MASLD trial addresses one of the most prevalent and undertreated metabolic conditions, for which there are currently no approved pharmaceutical treatments. This is potentially the compound's most important indication.

Diabetes control. The TRANSCEND-T2D-1 results showing 77–82% of patients achieving normal blood glucose represents a level of glycemic control that goes beyond what existing diabetes medications typically achieve.

Osteoarthritis pain. The TRIUMPH-4 knee pain data — one in eight patients becoming completely pain-free — suggests implications well beyond metabolic disease.

Once-weekly injectable. Same format as semaglutide and tirzepatide, which have proven acceptable to most patients.

The Cons and Cautions:

GI side effects are the most common and dose-dependent. At the highest dose, nausea affects approximately 43% of participants in Phase 3 data. Diarrhea, vomiting, and constipation follow similar patterns, most pronounced during dose escalation and typically diminishing at stable dose. This is consistent with the broader GLP-1 drug class but appears more pronounced at maximum doses of retatrutide than with tirzepatide.

Dysesthesia: a new finding worth understanding. Dysesthesia — abnormal skin sensations including tingling, burning, or altered touch perception — affected 20.9% of participants at 12 mg in Phase 3 trials and appears linked to the drug's glucagon receptor activity. This is a side effect not seen at the same rates with semaglutide or tirzepatide and is genuinely distinctive to retatrutide. It is mild in most cases, the mechanism is not fully understood, likely related to glucagon receptor activity in peripheral nerves, and most cases resolve at stable dose or after discontinuation. It is rarely painful and rarely causes treatment discontinuation. But affecting roughly one in five patients at the highest dose, it's not a minor caveat.

Treatment discontinuation rates rise with dose. In TRIUMPH-1, treatment discontinuation due to adverse events was approximately 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, compared with 4.9% in the placebo group. The highest-dose discontinuation rate is higher than what the established GLP-1 class typically shows.

Muscle and bone loss. Rapid weight loss of any kind — regardless of mechanism — reduces lean mass and bone mineral density. With retatrutide producing 24% average weight loss in Phase 2 and higher numbers in some Phase 3 subgroups, the bone effects are larger than seen with most other anti-obesity drugs. The GIP receptor component may be partially protective against bone loss (GIP receptors are present on bone cells), but the net effect at this magnitude of weight loss warrants monitoring. Resistance exercise during treatment s particularly important here.

Heart rate elevation. A dose-dependent rise of approximately 5–10 beats per minute was observed, peaking around week 24 and declining afterward. This pattern is consistent with other GLP-1 medications and hasn't been associated with adverse cardiovascular events in trial data, but cardiovascular outcome trial data for retatrutide specifically is still pending.

Long-term safety data is incomplete. The longest published exposure data runs to 68 weeks in Phase 3 and 48 weeks in Phase 2. No published two-year data exists yet. Known longer-term concerns include bone density loss, lean mass loss, gallbladder disease, and the dose-dependent dysesthesia signal, and the question of whether retatrutide can sustain 30%+ weight loss over years requires data that doesn't yet exist.

Weight regain on discontinuation. This applies to the entire GLP-1 class: weight loss is largely maintained only with continued use. The biology of obesity as a chronic condition means stopping the medication typically results in weight regain. Retatrutide doesn't appear to be different from its predecessors on this dimension. It's a treatment, but not a cure.

How It Compares to Current Options

For someone curious about where retatrutide fits relative to what's already available:

vs. Semaglutide (Wegovy/Ozempic): Retatrutide produces approximately twice the weight loss at comparable timepoints. Side effect burden is higher. Semaglutide has five-plus years of real-world safety data; retatrutide has less than two years of trial data.

vs. Tirzepatide (Zepbound/Mounjaro): The most meaningful comparison. Tirzepatide already outperforms semaglutide. Retatrutide appears to outperform tirzepatide on weight loss magnitude, and adds the liver fat benefit through glucagon receptor activity. The dysesthesia signal is more pronounced with retatrutide than tirzepatide. Tirzepatide is approved and available now.

The practical summary: for someone who achieves adequate results on tirzepatide with acceptable tolerability, retatrutide is not an obvious upgrade. For someone who hasn't responded sufficiently to tirzepatide, or who has significant liver disease as a primary indication, retatrutide represents a meaningful step forward.

What It Isn't

Retatrutide is not a research peptide. It's not available through gray-market channels, compounding pharmacies, or research-use-only vendors in any legitimate sense. It's an Eli Lilly proprietary drug in Phase 3 trials. Products appearing online labeled as "retatrutide" or "GLP-3" are unregulated, unverified compounds of unknown identity and purity. The FDA has issued direct concerns about unapproved GLP-1 drugs used for weight loss, and the same caution applies more forcefully to compounds not yet approved at all.

The only legitimate access to retatrutide today is through enrollment in one of the ongoing TRIUMPH clinical trials. Everything else is unknown chemistry sold under a familiar name.

The Bottom Line

Retatrutide represents a genuine pharmacological advance over existing approved options. The addition of glucagon receptor activity produces metabolic effects (energy expenditure, liver fat oxidation) that GLP-1 and dual GLP-1/GIP agonists can't fully replicate, and the weight loss numbers at Phase 3 are the largest ever produced by a pharmaceutical compound.

The trade-offs: higher GI upset at maximum doses, a new dysesthesia signal affecting roughly one in five patients at the highest dose, bone and muscle loss concerns from the magnitude of weight reduction, and a long-term safety profile that is still being built. The two-year cardiovascular outcome data that anchors prescribing confidence for semaglutide doesn't yet exist for retatrutide.

For someone evaluating the landscape: FDA approval is likely in 2027 pending submission and review. When it arrives, it will enter a market where tirzepatide is already established, making the competition for the next generation of metabolic medicine more interesting than it's been in years.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational compound not yet FDA-approved. Always consult a qualified healthcare provider before beginning any weight management medication.